Charles River has a strong drug discovery background in infectious disease and the assessment of novel anti-infectives such as antimicrobials, antivirals, and vaccines. We use a suite of methods to improve your understanding of the disease, host interactions, and treatment effects. Disease can be measured using in vitro infectious disease assays, conventional colony-forming units (CFU), or viral titre assessments, combined with clinical disease parameters and pharmacodynamic (PD) analysis. In addition, using protocols pioneered at Charles River, we have the ability to provide data from real-time in vivo bioluminescent imaging (IVIS), allowing you to follow the course of the disease and anti-infective treatment.
Figure 1: Real-time in vivo bioluminescent imaging (IVIS) of thigh infection in murine models. Bioluminescent bacteria allow quantification of infection progression and anti-infective treatment in-life.
Figure 2: A confocal microscopy image of a mouse lung tissue following H1N1 infection. Cell nuclei are DAPI stained blue, nucleoprotein antibody conferring to influenza H1N1 in green, and treatment in red. Yellow staining shows colocalization of the virus and therapeutic antibody.
A broad range of clinically relevant Gram-positive and Gram-negative species can be used in both proof-of-concept PD models and in specialized translational human disease models, all of which can be adapted to run with strains of your choice.
We also offer early screening of your anti-infective via our Galleria mellonella model to provide information on compound toxicity and efficacy and help design optimal dosing regimens, including the assessment of combination therapies, prior to use in murine models of infectious disease.
Our bacterial models include:
- Bacterial thigh infection
- Bacterial sepsis
- Bacterial peritonitis/septicemia
- Bacterial lung infection (acute/chronic)
- Bacterial skin/wound infection
- Bacterial otitis media (acute)
- Galleria Mellonella screening
- Otitis externa
- Urinary tract infection
- Clostridium difficile infection
- Group B streptococcus
Available bacterial strains include multidrug-resistant (MDR) pathogens:
- A. baumannii
- E. coli
- K. pneumoniae
- P. aeruginosa
- Staph. aureus (MSSA and MRSA)
- S. pneumoniae
Other bacterial strains are available via the American Type Culture Collection (ATCC).
Specialist virus models can be used to test your anti-infectives, antivirals and vaccines. These include:
- Herpes simplex virus
- Respiratory syncytial virus
- Encephalomyocarditis virus
- Tracking bacterial infection and treatment in Galleria mellonella using luminescent bacterium (poster)
- Combating AMR using the Wax Moth Larvae (blog)
- Correlating survival of Galleria mellonella with PKPD modelling of ciprofloxacin and meropenem (poster)
Webinar with our Principal Scientist for Anti-Infective Drug Discovery: Battle of the Bugs: Designing the Best Approach in the Fight Against Infectious Disease